NEW YORK (GenomeWeb) – Cepheid said today that it is broadening its collaboration with the Foundation for Innovative New Diagnostics to bring point-of-care tuberculosis diagnostics to all levels of the health system in low- and middle-income countries.

Specifically, the partners will evaluate the performance of Cepheid's new GeneXpert Omni system and Xpert MTB/RIF Ultra test, and assess the Omni's cloud-based connectivity. All resulting data from the evaluation will be made publicly available, Cepheid said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.